Although patients can receive intensive antibiotherapy and even granulocyte transfusions from healthy donors, the only current curative therapy is the hematopoietic stem cell transplant. However, progress has been made in gene therapy, an active area of research. Both foamyviral and lentiviral vectors expressing the human ITGB2 gene under the control of different promoters have been developed and have been tested so far in preclinical<unk> -I models (such as CD18-deficient mice and canine<unk> -affected dogs).
Leukocyte adhesion deficiency
Leukocyte adhesion molecule deficiency
Myeloperoxidase deficiency
Primary immunodeficiency
Neutrophil-specific granule deficiency
MBL deficiency
Combined immunodeficiencies
IgG deficiency